Fig. 2
The effect of CAR-147 macrophages on tumour growth in vivo. a In vivo imaging of luciferase-expressing HER2-4T1 tumour-bearing mice after intravenous injection of DiR-labelled Raw264.7 cells. b Quantitative analysis of the DiR fluorescence signal in the liver (n = 5). c Quantitative analysis of the DiR fluorescence signal at the tumour site (n = 5). d The experimental schedule for tumour implantation, macrophage infusion and bioluminescence imaging (BLI) monitoring. e BLI was performed on day 7 to assess tumour burden. Control Raw264.7 (CON) cells (1 × 106), CAR-147 Raw264.7 (147) cells (1 × 106), or PBS were injected i.v. on day 8 and day 15, and mice were followed with serial BLI. f The weight of tumours from control Raw264.7 cell- or CAR-147 Raw264.7 cell-treated mice was analysed. The data presented are pooled from two independent experiments. Each symbol indicates one mouse (n = 10). g The spleen weight of tumour-bearing mice was analysed. h The body weight of tumour-bearing mice was measured every 3 days. i Blood serum samples and tumour homogenates were collected from control Raw264.7 cell- or CAR-147 Raw264.7 cell-treated mice and analysed for proinflammatory cytokine release (IL-6, IFNγ, TNFα, IL-1β, IL-12) by ELISA (n = 5). All values are expressed as the mean ± SEM. *P < 0.05, **P < 0.01, and ***P < 0.001
